FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction
The Pharma Data
JANUARY 20, 2021
FDA Approves Verquvo (vericiguat) for Heart Failure with Reduced Ejection Fraction. The Verquvo label contains a boxed warning that indicates that Verquvo should not be administered to pregnant females because it may cause fetal harm. Related Articles: Verquvo (vericiguat) FDA Approval History. KENILWORTH, N.J.–(BUSINESS
Let's personalize your content